Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators.

N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.

PMID:
23121377
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.

Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.

Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17.

PMID:
21333426
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8.

PMID:
21903984
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.

Kidney Int. 2011 Aug;80(3):295-301. doi: 10.1038/ki.2011.119. Epub 2011 May 4.

PMID:
21544064
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.

Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT.

Kidney Int. 2013 Dec;84(6):1278-86. doi: 10.1038/ki.2013.285. Epub 2013 Jul 31.

PMID:
23903369
[PubMed - indexed for MEDLINE]
6.

Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Erickson KF, Chertow GM, Goldhaber-Fiebert JD.

Ann Intern Med. 2013 Sep 17;159(6):382-9. doi: 10.7326/0003-4819-159-6-201309170-00004.

PMID:
24042366
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators.

N Engl J Med. 2006 Nov 16;355(20):2099-112. Epub 2006 Nov 14.

PMID:
17105757
[PubMed - indexed for MEDLINE]
Free Article
8.

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P; ALADIN study group.

Lancet. 2013 Nov 2;382(9903):1485-95. doi: 10.1016/S0140-6736(13)61407-5. Epub 2013 Aug 21.

PMID:
23972263
[PubMed - indexed for MEDLINE]
9.

Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.

Aihara M, Fujiki H, Mizuguchi H, Hattori K, Ohmoto K, Ishikawa M, Nagano K, Yamamura Y.

J Pharmacol Exp Ther. 2014 May;349(2):258-67. doi: 10.1124/jpet.114.213256. Epub 2014 Feb 25.

PMID:
24570071
[PubMed - indexed for MEDLINE]
10.

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1319-31. Epub 2007 Mar 25.

PMID:
17384437
[PubMed - indexed for MEDLINE]
11.

Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.

Nemerovski C, Hutchinson DJ.

Clin Ther. 2010 Jun;32(6):1015-32. doi: 10.1016/j.clinthera.2010.06.015. Review.

PMID:
20637957
[PubMed - indexed for MEDLINE]
12.

Role of vasopressin antagonists.

Torres VE.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1212-8. doi: 10.2215/CJN.05281107. Epub 2008 Apr 23. Review.

PMID:
18434616
[PubMed - indexed for MEDLINE]
Free Article
13.

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE.

J Am Soc Nephrol. 2010 Jun;21(6):1052-61. doi: 10.1681/ASN.2009121291. Epub 2010 Apr 29.

PMID:
20431041
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT; DIPAK Consortium.

Am J Kidney Dis. 2014 Mar;63(3):446-55. doi: 10.1053/j.ajkd.2013.10.011. Epub 2013 Dec 15.

PMID:
24342522
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1332-43. Epub 2007 Mar 25.

PMID:
17384438
[PubMed - indexed for MEDLINE]
16.

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators.

Circulation. 2003 Jun 3;107(21):2690-6. Epub 2003 May 12.

PMID:
12742979
[PubMed - indexed for MEDLINE]
Free Article
17.

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF Jr, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.

Kidney Int. 2003 Sep;64(3):1035-45.

PMID:
12911554
[PubMed - indexed for MEDLINE]
18.

Volume progression in polycystic kidney disease.

Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators.

N Engl J Med. 2006 May 18;354(20):2122-30.

PMID:
16707749
[PubMed - indexed for MEDLINE]
Free Article
19.

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.

Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA.

J Am Coll Cardiol. 2007 Jun 5;49(22):2151-9. Epub 2007 May 18.

PMID:
17543634
[PubMed - indexed for MEDLINE]
Free Article
20.

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.

Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, Gansevoort RT, Torres VE; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP.

Am J Kidney Dis. 2013 Mar;61(3):420-9. doi: 10.1053/j.ajkd.2012.08.038. Epub 2012 Oct 22.

PMID:
23089511
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk